@ola09.bsky.social
Reposted
Oh my god I forgot about the Pinkerton thing too (this was Magic the Gathering related, but it does show how wacky WOTC was last year)
www.dicebreaker.com/categories/t...
www.dicebreaker.com/categories/t...
Magic: The Gathering publisher hires Pinkerton to seize leaked cards from YouTuber’s house
Magic: The Gathering's publisher sent Pinkerton investigators to a YouTube creator's house to seize unreleased cards.
www.dicebreaker.com
December 1, 2024 at 4:58 AM
Oh my god I forgot about the Pinkerton thing too (this was Magic the Gathering related, but it does show how wacky WOTC was last year)
www.dicebreaker.com/categories/t...
www.dicebreaker.com/categories/t...
Reposted
years). Twice-yearly lenacapavir was 89% more effective than once-daily Truvada (incidence rate ratio 0.11, p=0.00245). In the trial, Lenacapavir and Truvada were generally well-tolerated and no significant or new safety concerns were identified.
November 30, 2024 at 5:03 PM
years). Twice-yearly lenacapavir was 89% more effective than once-daily Truvada (incidence rate ratio 0.11, p=0.00245). In the trial, Lenacapavir and Truvada were generally well-tolerated and no significant or new safety concerns were identified.
Reposted
These results come from the PURPOSE 2 trial evaluating Gilead Sciences’ twice-yearly, subcutaneous Lenacapavir in individuals aged 16 years or older. Lenacapavir, which is a capsid inhibitor, is already approved by the FDA under the brand name Sunlenca for use alongside other
November 30, 2024 at 5:02 PM
These results come from the PURPOSE 2 trial evaluating Gilead Sciences’ twice-yearly, subcutaneous Lenacapavir in individuals aged 16 years or older. Lenacapavir, which is a capsid inhibitor, is already approved by the FDA under the brand name Sunlenca for use alongside other
We will be there 😁
November 30, 2024 at 7:26 PM
We will be there 😁